Analyze Diet
Pathogens (Basel, Switzerland)2022; 11(4); 400; doi: 10.3390/pathogens11040400

Equid Alphaherpesvirus 1 Modulates Actin Cytoskeleton and Inhibits Migration of Glioblastoma Multiforme Cell Line A172.

Abstract: Equid alphaherpesvirus 1 (EHV-1) causes respiratory diseases, abortion, and neurological disorders in horses. Recently, the oncolytic potential of this virus and its possible use in anticancer therapy has been reported, but its influence on cytoskeleton was not evaluated yet. In the following study, we have examined disruptions in actin cytoskeleton of glioblastoma multiforme in vitro model-A172 cell line, caused by EHV-1 infection. We used three EHV-1 strains: two non-neuropathogenic (Jan-E and Rac-H) and one neuropathogenic (EHV-1 26). Immunofluorescent labelling, confocal microscopy, real-time cell growth analysis and Oris cell migration assay revealed disturbed migration of A172 cells infected with the EHV-1, probably due to rearrangement of actin cytoskeleton and the absence of cell projections. All tested strains caused disruption of the actin network and general depolymerization of microfilaments. The qPCR results confirmed the effective replication of EHV-1. Thus, we have demonstrated, for the first time, that EHV-1 infection leads to inhibition of proliferation and migration in A172 cells, which might be promising for new immunotherapy treatment.
Publication Date: 2022-03-25 PubMed ID: 35456075PubMed Central: PMC9031356DOI: 10.3390/pathogens11040400Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research paper explores how a virus called Equid alphaherpesvirus 1 (EHV-1) that usually affects horses, can interfere with the growth and movement of cells in a type of brain cancer called glioblastoma multiforme. The study finds that the virus disrupts the structure of the cancer cells, slowing their growth and migration, which could have potential implications for new treatments.

Research Background

  • The focus of this study revolves around a virus called Equid alphaherpesvirus 1 (EHV-1). This virus is known to cause respiratory diseases, abortion, and neurological problems in horses. It was noted in prior studies that this virus may have an oncolytic potential, meaning it might be able to kill cancer cells. However, the previous research did not evaluate the influence of the virus on the cytoskeleton of cells.

Research Objective

  • The main aim was to examine the disruption caused by EHV-1 in the actin cytoskeleton of an in-vitro glioblastoma multiforme model (a brain cancer), particularly the A172 cell line. This is significant as a rearrangement of the actin cytoskeleton could inhibit the migration and growth of cancer cells, potentially slowing down the progression of the disease.

Research Methodology

  • Three stains of the EHV-1 virus were utilized for the study: two non-neuropathogenic (Jan-E and Rac-H) and one neuropathogenic (EHV-1 26).
  • Techniques like immunofluorescent labelling, confocal microscopy, real-time cell growth analysis, and the Oris cell migration assay were deployed to examine the effect of the virus on the A172 cells.

Research Findings

  • The research found that all strains of the EHV-1 virus tested disrupted the actin network of the A172 cells and led to a general depolymerization (breaking down) of microfilaments, part of the cell cytoskeleton involved in cell movement and shape.
  • Successful replication of the EHV-1 virus was confirmed via qPCR results.
  • Importantly, the researchers discovered that the EHV-1 virus led to inhibition of the A172 cells’ growth and migration. This suggests that the virus causes considerable disruption to the cells’ normal behavior.

Implications of the Research

  • This study showcases, for the first time, that the EHV-1 virus can inhibit proliferation and migration in A172 cells, part of a model for glioblastoma multiforme.
  • This finding is significant as it suggests potential for the virus to be used as a form of immunotherapy treatment for brain cancer. However, further research is necessary to explore this potential application fully.

Cite This Article

APA
Bartak M, Chodkowski M, Słońska A, Grodzik M, Szczepaniak J, Bańbura MW, Cymerys J. (2022). Equid Alphaherpesvirus 1 Modulates Actin Cytoskeleton and Inhibits Migration of Glioblastoma Multiforme Cell Line A172. Pathogens, 11(4), 400. https://doi.org/10.3390/pathogens11040400

Publication

ISSN: 2076-0817
NlmUniqueID: 101596317
Country: Switzerland
Language: English
Volume: 11
Issue: 4
PII: 400

Researcher Affiliations

Bartak, Michalina
  • Division of Microbiology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences, 02-786 Warsaw, Poland.
Chodkowski, Marcin
  • Division of Microbiology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences, 02-786 Warsaw, Poland.
  • Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-163 Warsaw, Poland.
Słońska, Anna
  • Division of Microbiology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences, 02-786 Warsaw, Poland.
Grodzik, Marta
  • Department of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, 02-786 Warsaw, Poland.
Szczepaniak, Jarosław
  • Department of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, 02-786 Warsaw, Poland.
Bańbura, Marcin W
  • Division of Microbiology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences, 02-786 Warsaw, Poland.
Cymerys, Joanna
  • Division of Microbiology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences, 02-786 Warsaw, Poland.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 38 references
  1. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs.. Nat Rev Drug Discov 2015 Sep;14(9):642-62.
    doi: 10.1038/nrd4663pmc: PMC7097180pubmed: 26323545google scholar: lookup
  2. Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.. Jpn J Clin Oncol 2019 Mar 1;49(3):201-209.
    doi: 10.1093/jjco/hyy170pubmed: 30462296google scholar: lookup
  3. Cymerys J, Dzieciatkowski T, Słońska A, Bierla J, Tucholska A, Chmielewska A, Golke A, Bańbura MW. Equine herpesvirus type 1 (EHV-1) replication in primary murine neurons culture.. Pol J Vet Sci 2010;13(4):701-8.
    doi: 10.2478/v10181-010-0022-3pubmed: 21370750google scholar: lookup
  4. Oladunni FS, Horohov DW, Chambers TM. EHV-1: A Constant Threat to the Horse Industry.. Front Microbiol 2019;10:2668.
    doi: 10.3389/fmicb.2019.02668pmc: PMC6901505pubmed: 31849857google scholar: lookup
  5. Courchesne MJ, White MC, Stanfield BA, Frampton AR Jr. Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells.. J Virol 2012 Mar;86(5):2882-6.
    doi: 10.1128/JVI.06296-11pmc: PMC3302254pubmed: 22205738google scholar: lookup
  6. Izdebska M, Zielińska W, Grzanka D, Gagat M. The Role of Actin Dynamics and Actin-Binding Proteins Expression in Epithelial-to-Mesenchymal Transition and Its Association with Cancer Progression and Evaluation of Possible Therapeutic Targets.. Biomed Res Int 2018;2018:4578373.
    doi: 10.1155/2018/4578373pmc: PMC5822767pubmed: 29581975google scholar: lookup
  7. Jayawardena N, Poirier JT, Burga LN, Bostina M. Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.. Oncolytic Virother 2020;9:1-15.
    doi: 10.2147/OV.S186337pmc: PMC7064293pubmed: 32185149google scholar: lookup
  8. Matthews JD, Morgan R, Sleigher C, Frey TK. Do viruses require the cytoskeleton?. Virol J 2013 Apr 18;10:121.
    doi: 10.1186/1743-422X-10-121pmc: PMC3639929pubmed: 23597412google scholar: lookup
  9. Walsh D, Naghavi MH. Exploitation of Cytoskeletal Networks during Early Viral Infection.. Trends Microbiol 2019 Jan;27(1):39-50.
    doi: 10.1016/j.tim.2018.06.008pmc: PMC6309480pubmed: 30033343google scholar: lookup
  10. Denes CE, Miranda-Saksena M, Cunningham AL, Diefenbach RJ. Cytoskeletons in the Closet-Subversion in Alphaherpesvirus Infections.. Viruses 2018 Feb 13;10(2).
    doi: 10.3390/v10020079pmc: PMC5850386pubmed: 29438303google scholar: lookup
  11. Lehmann MJ, Sherer NM, Marks CB, Pypaert M, Mothes W. Actin- and myosin-driven movement of viruses along filopodia precedes their entry into cells.. J Cell Biol 2005 Jul 18;170(2):317-25.
    doi: 10.1083/jcb.200503059pmc: PMC2171413pubmed: 16027225google scholar: lookup
  12. Roberts KL, Baines JD. Actin in herpesvirus infection.. Viruses 2011 Apr;3(4):336-46.
    doi: 10.3390/v3040336pmc: PMC3185702pubmed: 21994736google scholar: lookup
  13. Taylor MP, Koyuncu OO, Enquist LW. Subversion of the actin cytoskeleton during viral infection.. Nat Rev Microbiol 2011 Jun;9(6):427-39.
    doi: 10.1038/nrmicro2574pmc: PMC3229036pubmed: 21522191google scholar: lookup
  14. Słońska A, Cymerys J, Godlewski MM, Dzieciątkowski T, Tucholska A, Chmielewska A, Golke A, Bańbura MW. Equine herpesvirus type 1 (EHV-1)-induced rearrangements of actin filaments in productively infected primary murine neurons.. Arch Virol 2014 Jun;159(6):1341-9.
    doi: 10.1007/s00705-013-1949-3pmc: PMC4042010pubmed: 24352436google scholar: lookup
  15. Wu Y, Wei F, Tang L, Liao Q, Wang H, Shi L, Gong Z, Zhang W, Zhou M, Xiang B, Wu X, Li X, Li Y, Li G, Xiong W, Zeng Z, Xiong F, Guo C. Herpesvirus acts with the cytoskeleton and promotes cancer progression.. J Cancer 2019;10(10):2185-2193.
    doi: 10.7150/jca.30222pmc: PMC6584404pubmed: 31258722google scholar: lookup
  16. Słońska A, Cymerys J, Chodkowski M, Bąska P, Krzyżowska M, Bańbura MW. Human herpesvirus type 2 infection of primary murine astrocytes causes disruption of the mitochondrial network and remodeling of the actin cytoskeleton: an in vitro morphological study.. Arch Virol 2021 May;166(5):1371-1383.
    doi: 10.1007/s00705-021-05025-xpmc: PMC8036217pubmed: 33715038google scholar: lookup
  17. Walter I, Nowotny N. Equine herpes virus type 1 (EHV-1) infection induces alterations in the cytoskeleton of vero cells but not apoptosis.. Arch Virol 1999;144(9):1827-36.
    doi: 10.1007/s007050050707pubmed: 10542029google scholar: lookup
  18. Turowska A, Chmielewska A, Tucholska A, Bańbura MW. Wpływ zakażenia końskim herpeswirusem typu 1 (EHV-1) na aktynowe struktury szkieletu komórkowego. Med. Wet. 2007;63:80–83.
  19. Turowska A, Pajak B, Godlewski MM, Dzieciatkowski T, Chmielewska A, Tucholska A, Banbura M. Opposite effects of two different strains of equine herpesvirus 1 infection on cytoskeleton composition in equine dermal ED and African green monkey kidney Vero cell lines: application of scanning cytometry and confocal-microscopy-based image analysis in a quantitative study.. Arch Virol 2010 May;155(5):733-43.
    pubmed: 20349252doi: 10.1007/s00705-010-0622-3google scholar: lookup
  20. Chodkowski M, Słońska A, Bartak M, Bańbura MW, Cymers J. First report of the oncolytic effect of EHV-1 on the non-small lung cancer - in vitro studies.. Pol J Vet Sci 2021 Dec;24(4):607-610.
    pubmed: 35179844doi: 10.24425/pjvs.2021.139986google scholar: lookup
  21. Ning J, Wakimoto H. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.. Front Microbiol 2014;5:303.
    doi: 10.3389/fmicb.2014.00303pmc: PMC4064532pubmed: 24999342google scholar: lookup
  22. Suryawanshi YR, Schulze AJ. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?. Viruses 2021 Jul 2;13(7).
    doi: 10.3390/v13071294pmc: PMC8310195pubmed: 34372501google scholar: lookup
  23. White MC, Frampton AR Jr. The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells.. Cancer Gene Ther 2013 Feb;20(2):88-93.
    doi: 10.1038/cgt.2012.89pubmed: 23306611google scholar: lookup
  24. Zottel A, Jovčevska I, Šamec N, Komel R. Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review.. Crit Rev Oncol Hematol 2021 Apr;160:103283.
  25. Słońska A, Golke A, Solarska M, Cymerys J, Dzieciątkowski T, Bańbura M. Wpływ zakażeń wirusowych na cytoszkielet komórkowy. Post. Mikrobiol. 2011;50:121–130.
  26. Masoumi S, Harisankar A, Gracias A, Bachinger F, Fufa T, Chandrasekar G, Gaunitz F, Walfridsson J, Kitambi SS. Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design.. Drug Des Devel Ther 2016;10:2881-2897.
    pmc: PMC5026218pubmed: 27672311doi: 10.2147/dddt.s106196google scholar: lookup
  27. Bisaria A, Hayer A, Garbett D, Cohen D, Meyer T. Membrane-proximal F-actin restricts local membrane protrusions and directs cell migration.. Science 2020 Jun 12;368(6496):1205-1210.
    doi: 10.1126/science.aay7794pmc: PMC8283920pubmed: 32527825google scholar: lookup
  28. Pinto G, Saenz-de-Santa-Maria I, Chastagner P, Perthame E, Delmas C, Toulas C, Moyal-Jonathan-Cohen E, Brou C, Zurzolo C. Patient-derived glioblastoma stem cells transfer mitochondria through tunneling nanotubes in tumor organoids.. Biochem J 2021 Jan 15;478(1):21-39.
    doi: 10.1042/BCJ20200710pmc: PMC7800365pubmed: 33245115google scholar: lookup
  29. Valdebenito S, Audia A, Bhat KPL, Okafo G, Eugenin EA. Tunneling Nanotubes Mediate Adaptation of Glioblastoma Cells to Temozolomide and Ionizing Radiation Treatment.. iScience 2020 Sep 25;23(9):101450.
    doi: 10.1016/j.isci.2020.101450pmc: PMC7476317pubmed: 32882515google scholar: lookup
  30. Pontes B, Viana NB, Campanati L, Farina M, Neto VM, Nussenzveig HM. Structure and elastic properties of tunneling nanotubes.. Eur Biophys J 2008 Feb;37(2):121-9.
    doi: 10.1007/s00249-007-0184-9pubmed: 17598104google scholar: lookup
  31. Kurtz BM, Singletary LB, Kelly SD, Frampton AR Jr. Equus caballus major histocompatibility complex class I is an entry receptor for equine herpesvirus type 1.. J Virol 2010 Sep;84(18):9027-34.
    doi: 10.1128/JVI.00287-10pmc: PMC2937649pubmed: 20610718google scholar: lookup
  32. Marelli G, Howells A, Lemoine NR, Wang Y. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.. Front Immunol 2018;9:866.
    doi: 10.3389/fimmu.2018.00866pmc: PMC5932159pubmed: 29755464google scholar: lookup
  33. Marchini A, Scott EM, Rommelaere J. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.. Viruses 2016 Jan 6;8(1).
    doi: 10.3390/v8010009pmc: PMC4728569pubmed: 26751469google scholar: lookup
  34. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering.. Mol Ther 2007 Apr;15(4):651-9.
    doi: 10.1038/sj.mt.6300108pubmed: 17299401google scholar: lookup
  35. Cymerys J, Słońska A, Brzezicka J, Tucholska A, Chmielewska A, Rola J, Malik P, Bańbura MW. Replication kinetics of neuropathogenic and non-neuropathogenic equine herpesvirus type 1 (EHV-1) strains in primary murine neurons and ED cell line.. Pol J Vet Sci 2016 Dec 1;19(4):777-784.
    doi: 10.1515/pjvs-2016-0098pubmed: 28092604google scholar: lookup
  36. Malik P, Pálfi V, Bálint A. Development of a new primer-probe energy transfer method for the differentiation of neuropathogenic and non-neuropathogenic strains of equine herpesvirus-1.. J Virol Methods 2010 Nov;169(2):425-7.
  37. Dzieciatkowski T, Przybylski M, Cymerys J, Turowska A, Chmielewska A, Tucholska A, Banbura MW. Equine herpesvirus type 1 quantification in different types of samples by a real-time PCR.. Pol J Vet Sci 2009;12(3):311-5.
    pubmed: 19886251
  38. Hulkower KI, Herber RL. Cell migration and invasion assays as tools for drug discovery.. Pharmaceutics 2011 Mar 11;3(1):107-24.

Citations

This article has been cited 0 times.